Zymeworks appoints Dr. Neil Gallagher to board; 6th new director in 12 months

Zymeworks Inc.

Dr. Gallagher joins board effective April 2, 2024 as Class I director, term to 2025 AGM.
He will receive initial option grant for 74,000 common shares on appointment.
Gallagher appointed to R&D committee; full committee composition updated (see filing).
Gallagher is President & Head of R&D at Syndax Pharmaceuticals; ex-AbbVie, Amgen, Novartis.
CEO says appointment supports advancement of '5 by 5' clinical programs and pipeline expansion.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Neil Gallagher

director

ZYME · Zymeworks Inc.

Effective: 2024-04-02
Filed: March 28, 2024, 7:59 PM ET

On March 27, 2024, the board of directors (the “Board”) of Zymeworks Inc. (the “Company”), upon recommendation from the nominating and corporate governance committee of the Board, appointed Dr. Neil Gallagher as a director of the Company, effective as of April 2, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Dr. Neil Gallagher was appointed as director at Zymeworks Inc..

Action: appointed
Role: director

Exact text from the filing

On March 27, 2024, the board of directors (the “Board”) of Zymeworks Inc. (the “Company”), upon recommendation from the nominating and corporate governance committee of the Board, appointed Dr. Neil Gallagher as a director of the Company, effective as of April 2, 2024.

View on SEC.gov

Zymeworks Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-080641

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.